Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have been given a consensus rating of “Moderate Buy” by the eight research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $8.9167.

A number of equities analysts recently commented on XERS shares. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 18th. Zacks Research raised shares of Xeris Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th. HC Wainwright initiated coverage on shares of Xeris Biopharma in a report on Tuesday, August 12th. They set a “buy” rating and a $10.00 price objective for the company. Leerink Partners lifted their price objective on shares of Xeris Biopharma from $7.00 to $9.00 and gave the company an “outperform” rating in a report on Tuesday, August 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, October 8th.

Insider Activity at Xeris Biopharma

In related news, Director Marla Persky sold 15,500 shares of Xeris Biopharma stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $7.72, for a total transaction of $119,660.00. Following the completion of the sale, the director owned 142,000 shares in the company, valued at $1,096,240. This trade represents a 9.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director John Johnson sold 107,500 shares of Xeris Biopharma stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $7.32, for a total transaction of $786,900.00. Following the sale, the director owned 833,483 shares of the company’s stock, valued at $6,101,095.56. The trade was a 11.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 207,732 shares of company stock worth $1,550,437. Corporate insiders own 6.47% of the company’s stock.

Institutional Investors Weigh In On Xeris Biopharma

Several large investors have recently modified their holdings of XERS. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Xeris Biopharma by 92.1% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 31,254 shares of the company’s stock valued at $172,000 after purchasing an additional 14,986 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Xeris Biopharma by 11.8% in the 1st quarter. Bank of New York Mellon Corp now owns 360,324 shares of the company’s stock valued at $1,978,000 after purchasing an additional 37,949 shares in the last quarter. Cerity Partners LLC raised its holdings in shares of Xeris Biopharma by 107.3% in the 1st quarter. Cerity Partners LLC now owns 31,851 shares of the company’s stock valued at $175,000 after purchasing an additional 16,484 shares in the last quarter. Xponance Inc. bought a new stake in shares of Xeris Biopharma in the 1st quarter valued at about $57,000. Finally, Gateway Wealth Partners LLC bought a new stake in shares of Xeris Biopharma in the 1st quarter valued at about $92,000. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Trading Up 0.9%

XERS opened at $9.71 on Friday. The firm has a market cap of $1.57 billion, a P/E ratio of -46.24 and a beta of 0.39. Xeris Biopharma has a 12 month low of $2.82 and a 12 month high of $10.02. The stock has a 50-day moving average of $8.24 and a 200 day moving average of $6.16.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02. The firm had revenue of $67.71 million for the quarter, compared to analysts’ expectations of $64.58 million. On average, research analysts forecast that Xeris Biopharma will post -0.41 earnings per share for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.